| Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide … MV Mateos, A Oriol, J Martínez-López, N Gutiérrez, AI Teruel, R de Paz, ... The lancet oncology 11 (10), 934-941, 2010 | 613 | 2010 |
| Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in … MV Mateos, PG Richardson, R Schlag, NK Khuageva, MA Dimopoulos, ... Journal of Clinical Oncology 28 (13), 2259-2266, 2010 | 590 | 2010 |
| Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study MV Mateos, JM Hernández, MT Hernández, NC Gutiérrez, L Palomera, ... Blood 108 (7), 2165-2172, 2006 | 538 | 2006 |
| Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial MV Mateos, M Cavo, J Blade, MA Dimopoulos, K Suzuki, A Jakubowiak, ... The Lancet 395 (10218), 132-141, 2020 | 471 | 2020 |
| Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are … JJ Lahuerta, MV Mateos, J Martínez-López, L Rosinol, A Sureda, ... Journal of Clinical Oncology 26 (35), 5775-5782, 2008 | 360 | 2008 |
| Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 … MA Dimopoulos, E Terpos, M Boccadoro, S Delimpasi, M Beksac, ... The Lancet Oncology 22 (6), 801-812, 2021 | 330 | 2021 |
| Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma C Perez, C Botta, A Zabaleta, N Puig, MT Cedena, I Goicoechea, ... Blood, The Journal of the American Society of Hematology 136 (2), 199-209, 2020 | 111 | 2020 |
| Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data A Mosquera Orgueira, MS González Pérez, JÁ Díaz Arias, ... Leukemia 35 (10), 2924-2935, 2021 | 41 | 2021 |
| Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair AA López-Iglesias, AB Herrero, M Chesi, L San-Segundo, ... Journal of Hematology & Oncology 10, 1-14, 2017 | 34 | 2017 |
| The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma S Hernández-García, L San-Segundo, L González-Méndez, LA Corchete, ... Haematologica 102 (12), 2113, 2017 | 30 | 2017 |
| A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies MA Dawson, G Borthakur, BJP Huntly, A Karadimitris, A Alegre, ... Clinical Cancer Research 29 (4), 711-722, 2023 | 19 | 2023 |
| DREAMM-4: Evaluating safety and clinical activity of belantamab mafodotin in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM) AK Nooka, MV Mateos Manteca, N Bahlis, K Weisel, A Oriol, ... The 25th European Hematology Association Annual Congress (EHA25 Virtual), 2020 | 12 | 2020 |
| MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma. MV Mateos Manteca, S Grosicki, K Kim, E Negre, E Vandendries Journal of Clinical Oncology 41 (16_suppl), TPS8066-TPS8066, 2023 | 9 | 2023 |
| Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation FA de la Fuente, MS Durán, MÁ Álvarez, IL Sanromán, AM Dios, ... Seminars in hematology 55 (4), 189-196, 2018 | 5 | 2018 |
| Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing … IG Escobar, PT Alonso, DC Barrigon, JA Perez-Simon, ... Annals of nuclear medicine 22, 251-260, 2008 | 4 | 2008 |
| Tratamiento del mieloma múltiple asintomático: recomendaciones del Grupo Español de Mieloma MVM Manteca, J Bladé, JJ Lahuerta, JF San Miguel Medicina clínica 148 (11), 517-523, 2017 | 3 | 2017 |
| Cystatin C‐Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma FJ Cepeda-Piorno, E González-García, A Méndez-Gallego, ... Advances in Hematology 2022 (1), 4282226, 2022 | 2 | 2022 |
| DREAMM-7: A phase III study of the efficacy and safety of belantamab mafodotin with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma R Rifkin, K Boyd, S Grosicki, K Kim, F Di Raimondo, M Dimopoulos, ... BRITISH JOURNAL OF HAEMATOLOGY 193, 172-173, 2021 | 2 | 2021 |
| Characterization and Management of Ocular Events in Patients Treated with Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in the DREAMM-8 Study H Quach, M Dimopoulos, M Beksac, L Pour, S Delimpasi, V Vorobyev, ... CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 24, S273-S273, 2024 | 1 | 2024 |
| Characterization and Management of Ocular Events in Patients (Pts) Treated with Belantamab Mafodotin (Belamaf) Plus Bortezomib and Dexamethasone (BVd) in the DREAMM-7 Study V Hungria, P Robak, M Hus, C Fu, V Zherebtsova, C Ward, PJ Ho, ... CIG MEDIA GROUP, LP, 2024 | 1 | 2024 |
